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Sir,
We have read with great interest the article by Korkeila et al
(2009) ‘Expression of carbonic anhydrase IX suggests poor
outcome in rectal cancer’ in a recent issue of the British Journal
of Cancer. As the authors rightly state, CA-IX has been found to be
of clinical value in different tumour types. The authors, however,
state that their study was ‘designed to assess the prognostic and
predictive value of CA-IX in rectal cancer treated by either short or
long course of radiotherapy’. Although this might be the case, their
data analysis does not support this statement.
The prognostic value of CA-IX, if present, cannot be deduced
from the applied patient cohort, as all patients received radio-
and/or chemotherapy. A pure prognostic factor can only be
detected in an untreated patient population. CA-IX is also known
to be strongly induced by hypoxia through HIF1a upregulation
(Lal et al, 2001). The hypoxic phenotype that is represented by the
high expression levels of CA-IX is very likely to cause a predictive
value of CA-IX, predicting in this case resistance to radiotherapy
and possibly also chemotherapy. Earlier, we have found CA-IX to
be predictive for different adjuvant treatments in breast cancer
(Span et al, 2003).
On the other hand, the authors also describe a control group
that would seem to have received no neoadjuvant chemo- or
radiotherapy. If these patients also did not receive adjuvant
therapy, which is regrettably unclear from the paper, the authors
should be able to determine whether the clinical value of CA-IX is
similar in treated and untreated rectal cancer patients. This could
add valuable information to this subject and would warrant
publication.
In our opinion, the results shown so far only allow the statement
‘Expression of Carbonic Anhydrase IX suggests poor response to
therapy in rectal cancer’.
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